1541 fundamentals
IMMUNEONCO BIOPHARMACEUTICALS (SHAN financial statements, including revenue, expenses, and profit
The total revenue of 1541 for the last semiannual is 80.35 M HKD, and it's 96203.02% higher compared to the previous semiannual. The net income of H2 24 is -163.62 M HKD.
Total revenue
Gross profit
Operating income
Pretax income
Net income
Currency: HKD
TTM